Interview with Glib Zagoriy, CEO, Darnitsa
Considering you only took over as CEO from your father in 2009, what was the mandate that was given to you as new CEO of the company – including your…
Address: ZAO Darnitsa Pharmaceutical Firm, 13 Ulitsa Borispolskaya, Kiev, 02093,Ukraine
Tel: (+38 044) 207-73-18
Web: http://darnitsa.ua/
In October 1930 the Ukrainian Institute of Experimental Endocrinology was founded in the Ukrainian capital Kiev. Few people then knew that the new buildings of the institute, built in 1938 in the Darnytskyi district of the capital, would be the basis of the largest chemical and pharmaceutical association in Ukraine. Darnitsa gave a powerful impetus to the development of modern pharmaceutical industry in Ukraine. The modern history of the company began in 1994, when the company was significantly reorganized.
Darnitsa’s use of innovative technologies and equipment along with compliance with the GMP and the introduction of quality management guarantees the production of a wide range of products under controlled conditions and ensures flexibility and mobility of production, optimal pricing and high quality and efficiency.
Darnitsa invest a significantly, not only in research and technology development, but also in the development of human resources. Effective use of the intellectual capacity of the staff – that the success of their business.
Antibiotics
Considering you only took over as CEO from your father in 2009, what was the mandate that was given to you as new CEO of the company – including your…
It has been almost a decade since Mili Healthcare began its operations in Ukraine today becoming one of the top 20 leading foreign companies in the local industry. What were…
What was the vision behind the creation of APRaD back in 2007 and what was lacking in the market at that time that called for such an association? APRaD originated…
You recently switched from Novartis to Unipharm. Given the major differences in environment and portfolio, what was it about Unipharm in particular that attracted you and what are you bringing…
Since 2006 Teva has been on a solid phase of growth and consolidation, mainly through the acquisitions of IVAX in 2006, Pliva (Barr) in 2008 and ratiopharm in 2010, which…
If you could provide our readers with your philosophy when you founded Sayenko Kharenko in 2004. What were the market needs that were perhaps missing that you identified and wanted…
It has been one year since you were appointed as the head of UCB’s operations in Ukraine. What was the mission of your assignment when you took this position and…
Considering you only took over as CEO from your father in 2009, what was the mandate that was given to you as new CEO of the company – including your…
Orion’s global strategy focuses on the CIS and Eastern European markets that still exhibit large growth potential and are expanding, despite a reverse trend for the rest of the industry.…
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Since the establishment of Astellas’ predecessor Brocade in Russia in 1992, what has been Astellas’ evolution in Ukraine? Astellas has been present in Ukraine for 16 years, first as Yamanouchi…
See our Cookie Privacy Policy Here
